Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors. 2018

Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
Tokyo New Drug Research Laboratories, Pharmaceutical Division, Kowa Co., Ltd., 2-17-43, Noguchicho, Higashimurayama, Tokyo 189-0022, Japan. Electronic address: k-sibuya@kowa.co.jp.

We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure-activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands-N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)-via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3hin vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008297 Male Males
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002785 Sterol O-Acyltransferase An enzyme that catalyzes the formation of cholesterol esters by the direct transfer of the fatty acid group from a fatty acyl CoA derivative. This enzyme has been found in the adrenal gland, gonads, liver, intestinal mucosa, and aorta of many mammalian species. EC 2.3.1.26. Acyl-CoA-Cholesterol Acyltransferase,Cholesterol Acyltransferase,Cholesterol Esterifying Enzyme,Acyl CoA Cholesterol Acyltransferase,Acyltransferase, Acyl-CoA-Cholesterol,Acyltransferase, Cholesterol,Enzyme, Cholesterol Esterifying,Esterifying Enzyme, Cholesterol,O-Acyltransferase, Sterol,Sterol O Acyltransferase
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
February 2001, Nihon rinsho. Japanese journal of clinical medicine,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
July 1999, Bioorganic & medicinal chemistry letters,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
January 1994, Journal of enzyme inhibition,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
April 2013, European journal of medicinal chemistry,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
November 1996, Chemical & pharmaceutical bulletin,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
July 1997, Bioorganic & medicinal chemistry,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
December 2004, Nihon rinsho. Japanese journal of clinical medicine,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
December 1997, Planta medica,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
March 2006, Archives of pharmacal research,
Kimiyuki Shibuya, and Katsumi Kawamine, and Toru Miura, and Chiyoka Ozaki, and Toshiyuki Edano, and Ken Mizuno, and Yasunobu Yoshinaka, and Yoshihiko Tsunenari
May 2024, Biochimica et biophysica acta. Molecular and cell biology of lipids,
Copied contents to your clipboard!